#PHIO

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance Sheet with $23.7 Million in Net Proceeds, Extending Cash Runway into the First Half of 2027 King of

1 week ago

#PHIO Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing

1 week ago

#PHIO Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

2rZiKKbOU3nTafniR2qMMSE0gwZ

@2rzikkbou3ntafnir2qmmse0gwz.activitypub.awakari.com.ap.brid.gy

2 weeks ago

Quantum XChange Adds EUCC Compliance Mode to Phio TX Insider Brief PRESS RELEASE — Quantum XChange today announced the latest release of its cryptographic management platform Phio TX® which int...

#Daily #EU #cybersecurity #regulation #EUCC […]

[Original post on thequantuminsider.com]

0 0 0 0

Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference Phio Pharmaceuticals (NASDAQ: PHIO) will present at the 3rd Annual DealFlow Discovery Conference on January 28, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman, will deliver the company presentation on January 28 at 9:00 AM ET in Borgata Hotel Room #1, and management will be available for one-on-one investor meetings during the event.The company noted completion of treatment in the Phase 1b trial for PH-762 and emphasized ongoing development of therapeutics using its proprietary INTASYL gene silencing technology targeting cancer.

1 month ago

#PHIO Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a

1 month ago

#PHIO Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary

2 months ago

#PHIO Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 Phio Pharmaceuticals (NASDAQ: PHIO) announced completion of enrollment in its Phase 1b trial of INTASYL siRNA lead PH-762 for cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma.Key facts: 18 patients treated across five dose-escalating cohorts; in 16 cSCC patients there were 6 complete responses, 2 near-complete and 2 partial responses; one Merkel cell carcinoma patient had a partial response; no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects reported.Additional patients are being treated in the fifth cohort at the highest dose and pathology results are expected in Q1 2026.

3 months ago

#PHIO Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress Phio Pharmaceuticals (NASDAQ: PHIO) will present a podium talk on its INTASYL siRNA Drug Technology at Advanced Therapies USA 2025 in Philadelphia on November 18, 2025. The presentation, titled "INTASYL® Synthesized siRNA Drug Technology Down-regulating Gene Expression," will be delivered by Melissa Maxwell, M.S. in the Innovation Showcase (Track 2, Seminar Theatre) at 1:15 PM EDT. The company described INTASYL and PH-762 as a promising approach to enhance cancer treatment and a potential non-surgical option for cutaneous carcinomas.Event dates are November 18–19, 2025 at the Pennsylvania Convention Center.

3 months ago

#PHIO Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Phio Pharmaceuticals (NASDAQ: PHIO) reported Q3 2025 results and a business update on November 13, 2025. Key clinical and financing developments include advancement to the fifth and final dose cohort for intratumoral INTASYL PH-762 and pathology at maximum dose showing 100% tumor clearance in 1 patient, >90% clearance in a second, and >50% clearance in a third at Day 36.Cumulative cSCC results: 6 complete responses among 16 cSCC patients. No dose-limiting toxicities reported. The company completed warrant inducement financings expected to raise ~$12.1 million, and estimates cash of ~$21.3 million, projecting runway into H1 2027.

4 months ago

#PHIO Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

4 months ago

🚨 FeetrAI Alert: #PHIO is in the spotlight! Trading at $1.5619, it's oversold with potential for a short-term rebound. But beware, MACD signals ongoing bearish momentum. Consider a SHORT position targeting $1.45 & $1.35, with a stop loss at $1.65. Watch for volume spikes! 📉 #Biotech #Stocks

0 0 0 0

4 months ago

🚨 FeetrAI Alert: #PHIO is in the spotlight! Trading at $1.5619, it's showing bearish vibes with oversold RSI hinting at a bounce. MACD's still negative though. Volatility is high post-clinical news. Consider SHORT at $1.56, target $1.45/$1.35, stop loss $1.65. 📉 #BiotechBuzz

0 0 0 0

4 months ago

🚀 Exciting times for #PHIO! Despite bearish momentum and volatility, oversold RSI hints at a potential rebound. Recent clinical data sparks optimism, but caution is key with biotech penny stocks. Short entry: $1.60, targets: $1.45 & $1.30. Stop loss: $1.70. 📉💡 #FeetrAI

0 0 0 0

4 months ago

🚨 Bearish Alert on #PHIO! Trading at $1.53, Phio Pharmaceuticals shows oversold RSI <20 and a negative MACD histogram. Low volume hints at limited buying interest. Consider shorting at $1.55 with targets at $1.45 & $1.35. Stop loss: $1.60. Stay vigilant for news! 📉 #FeetrAI

0 0 0 0

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program Phio Pharmaceuticals (NASDAQ: PHIO) announced on November 7, 2025 that its INTASYL compound PH-762 won the 2025 Immunomodulatory Solution of the Year award from the BioTech Breakthrough Awards program.The company is a clinical-stage biopharmaceutical developer using its proprietary INTASYL siRNA gene‑silencing platform focused on cancer therapies. Company leadership highlighted PH-762 as an intratumoral immunotherapy intended to enhance cancer treatment efficacy, and the award organization noted PH-762 addresses a medical need for non‑surgical options for cutaneous carcinomas.

4 months ago

#PHIO Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

4 months ago

🚨 FeetrAI Alert: #PHIO is in the spotlight! Recent clinical data sparks interest, but technicals flash caution. RSI shows oversold, MACD bearish, trading below 10-day SMA. Low volume = sharp moves. Consider SHORT at $1.60, targets: $1.50 & $1.40. Stop loss: $1.65. 📉 #Stocks

0 0 0 0

4 months ago

🚨 FeetrAI Alert: #PHIO is trading at $1.69, well below its 10-day SMA of $2.04! With an RSI of 8.29, it's heavily oversold and primed for a bounce. But beware, MACD is still negative. Short entry at $1.70, targets at $1.50 & $1.30. Stop loss at $1.80. 📉 #BiotechVolatility

0 0 0 0

@smcapstrategist.bsky.social

4 months ago

🚨 Hot take on #PHIO! Volatility is high with recent clinical data shaking things up. 📉 Bearish trend alert: Price at $1.64, below key MAs, but RSI hints at a bounce. MACD says caution! Consider shorting at $1.70, targets: $1.50 & $1.30. Stop loss: $1.80. Stay sharp! 🔍 #Biotech #FeetrAI

0 0 0 0

Small Cap Strategist

4 months ago

Most Searched, Monday November 3, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Nov 3rd - #LAES #QURE #NVTS #TERN #SLDP #THAR #RXRX #AREC #FUBO #DVLT #CRBU #NVAI #ONDS #RR #PHIO #WRD #PLUG #BBAI #NNVC #CRML - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

4 months ago

🚀 Big moves for #PHIO! Trading volume skyrockets on promising clinical data, but caution is key. RSI hints at a rebound, yet MACD stays bearish. Current price $1.7979 below key averages. Short at $1.80? Targets: $1.60 & $1.40. Stop loss: $2.00. Stay sharp, biotech is wild! 📈 #FeetrAI

0 0 0 0

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds Phio Pharmaceuticals (NASDAQ: PHIO) announced definitive agreements to exercise outstanding warrants to purchase an aggregate of 5,663,182 shares of common stock at exercise prices between $2.00 and $5.45, producing expected gross proceeds of approximately $13.4 million before placement agent fees and offering expenses.The offering closes in two tranches (first close on or about Nov 4, 2025, second close by Nov 18, 2025). Exercising holders will pay an additional $0.125 per new unregistered warrant ($1,415,795.50 aggregate) and receive new unregistered warrants to purchase up to 11,326,364 shares at a $2.05 exercise price, immediately exercisable with a 24‑month term following the resale registration effective date.Phio intends to use net proceeds for working capital and to accelerate development activities for PH-762 in cutaneous carcinomas after recent positive safety and pathology results.

4 months ago

#PHIO Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Stock Master

@stockmaster70.bsky.social

4 months ago

📢 Stocks Trending NOW: #IREN #KVUE #KMB #CIFR #QURE #CRBU #PHIO #IOVA #FUBO #MSPR

0 0 0 0

4 months ago

🚀 Exciting times for #PHIO! With positive trial results and partnership buzz, the stock has jumped from $2.08 to $4.41! 📈 Bullish momentum is strong, but watch for volatility. Consider entering at $4.30, targeting $5.00 & $5.50. Stay sharp, traders! #FeetrAI #StockMarket

0 0 0 0

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial Pathologic Clearance: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Pathologic Results Assessed at Approximately 5 Weeks Safety Monitoring Committee Issues Favorable Review

4 months ago

#PHIO Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

www.stocktitan.net/news/PHIO/phio-pharmaceu...

1 0 0 0

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2025 financial results and provided updates on its Phase 1b clinical trial for PH-762. The trial, evaluating intratumoral PH-762 in various skin cancers, has treated 15 patients across four cohorts with promising results. Among 13 cSCC patients, 5 achieved complete response, 1 near-complete response, and 1 partial response.The company's cash position strengthened to $10.8 million as of June 30, 2025, up from $5.4 million in December 2024. Q2 2025 resulted in a net loss of $2.2 million, compared to $1.8 million in Q2 2024. In July 2025, Phio raised an additional $2.2 million through warrant exercises.

7 months ago

#PHIO Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds Phio Pharmaceuticals (NASDAQ: PHIO) has secured approximately $2.5 million in gross proceeds through the exercise of outstanding warrants. The agreement involves the exercise of warrants to purchase 928,596 shares of common stock, with 100,000 shares at $2.00 per share and 828,596 shares at a reduced price of $2.485 per share.In exchange for immediate cash exercise, holders will receive new unregistered warrants for up to 1,857,192 shares at $2.485 per share. These new warrants include two tranches: one with a 24-month term for 1,538,596 shares and another with a 5-year term for 318,596 shares. The offering, managed by H.C. Wainwright & Co., is expected to close around July 28, 2025.

7 months ago

#PHIO Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort Phio Pharmaceuticals (NASDAQ: PHIO) has announced pathology results for four out of five patients in the fourth cohort of its Phase 1b clinical trial for PH-762. The trial evaluates the intratumoral use of PH-762 in various skin cancers. Key results include a complete pathologic response in one cutaneous squamous cell carcinoma (cSCC) patient and a partial response in a Stage 4 metastatic Merkel cell patient.Across all four cohorts, 15 patients have been treated with no dose-limiting toxicities or clinically relevant adverse effects. Among 13 cSCC patients, five achieved complete response, one near-complete response, one partial response, and six non-responses. The company is now enrolling what is expected to be the final cohort in the Phase 1b study.

7 months ago

#PHIO Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Phio Pharmaceuticals Advances Cancer Drug Production with Strategic US Manufacturing Partnership New US manufacturing agreement accelerates development of PH-762 cancer therapeutic. Key milestone for Phase 1b trial progression. Get details on strategic expansion.

7 months ago

#PHIO Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort Phio Pharmaceuticals (NASDAQ: PHIO) reported positive safety results from the fourth cohort of its Phase 1b clinical trial for PH-762, their lead siRNA compound for skin cancer treatment. The Safety Monitoring Committee recommended advancing to the fifth and expected final dose escalation cohort.The trial has treated 15 total patients across four cohorts, including 13 with cutaneous squamous cell carcinoma (cSCC), one with metastatic melanoma, and one with Merkel cell carcinoma. Notable results from the first three cohorts showed complete response in 4 of 9 cSCC patients, with additional patients showing near complete or partial responses. No dose-limiting toxicities or serious adverse events were reported.

8 months ago

#PHIO Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

www.stocktitan.net/news/PHIO/phio-pharmaceu...

0 0 0 0